Hesteriosciences share price
You have to be logged in to add this to Watchlist.- ₹1,350.00(4.90%)March 13, 2025 15:29:10 PM IST
- NSE
- BSE
- Vol : 28.28K (NSE + BSE)Last 20 day avg : 11.37 K
Hesteriosciences is trading 4.90% upper at Rs 1,350.00 as compared to its last closing price. Hesteriosciences has been trading in the price range of 1,380.00 & 1,272.80. Hesteriosciences has given -43.64% in this year & -6.29% in the last 5 days. Hesteriosciences has TTM P/E ratio 64.76 as compared to the sector P/E of 27.72.The company posted a net profit of 11.66 Crores in its last quarter.Listed peers of Hesteriosciences include Syncom Formulations India (-0.76%), Bliss Gvs Pharma (-2.02%), Hesteriosciences (4.90%).The Mutual Fund holding in Hesteriosciences was at 0.03% in 31 Dec 2022. The MF holding has decreased from the last quarter. The FII holding in Hesteriosciences was at 0.59% in 31 Dec 2024. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Mar 15, 2025, 05:23 PM UTC
- Dividend YieldLower than industry0.44Annual dividends as a percentage of the stock price.
- P/BLower than historical values3.94The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values36.50Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility1.47Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.84The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable
The company's revenue fell during December quarter by 5.62% from Rs 66.98 crore to Rs 63.22 crore, year-on-year- The company has grown its December quarter profit by 192.72% from Rs 3.98 crore to Rs 11.66 crore, year-on-year
- The debt to equity of the company is higher than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,620.75
- R2
- 1,741.05
- R3
- 1,917.75
- S1
- 1,323.75
- S2
- 1,147.05
- S3
- 1,026.75
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Syncom Formulations India | Bearish | 15.61 | -0.76 | 1,467.34 | 55.04 | 5.08 | - | - |
| Bliss Gvs Pharma | Bearish | 114.10 | -2.02 | 1,202.27 | 12.68 | 1.24 | 0.44 | 4.64 |
| Hesteriosciences | Bearish | 1,350.00 | 4.90 | 1,148.42 | 63.59 | 3.94 | 0.44 | 64.12 |
| Shukra Pharmaceuticals | Bullish | 245.80 | 1.99 | 1,076.31 | 58.06 | 18.67 | 0.41 | 4.61 |
| Lincoln Pharmaceuticals | Bearish | 527.30 | 0.10 | 1,053.82 | 11.31 | 1.78 | 0.34 | - |
- Promoter(s) holds a high stake in the company at 53.73%
- FIIs are invested in this company
- FIIs holding has decreased by 0.02 percentage points from previous quarter
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-01-30 | Quarterly Results |
| 2024-10-28 | Quarterly Results |
| 2024-08-02 | Quarterly Results |
| 2024-05-10 | Audited Results & Dividend |
| 2024-02-02 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE782E01017
- BSE Code524669
- NSE CodeHESTERBIO
Hesteriosciences is trading at 1350.00 as on Thu Mar 13 2025 09:59:10. This is 4.90% upper as compared to its previous closing price of 1286.95.
The market capitalization of Hesteriosciences is 1148.42 Cr as on Thu Mar 13 2025 09:59:10.
The 52 wk high for Hesteriosciences is 3375.45 whereas the 52 wk low is 1267.35
Hesteriosciences can be analyzed on the following key metrics -
- TTM P/E: 64.76
- Sector P/E: 27.72
- Dividend Yield: 0.44%
- D/E ratio: -
Hesteriosciences reported a net profit of 18.89 Cr in 2024.
The Mutual Fund Shareholding was 0.03% at the end of 31 Dec 2022.